Active surveillance for localized prostate cancer : a new paradigm for clinical management

Front Matter ....Pages i-xii
 Cancer Overdiagnosis and Overtreatment  (Laurence Klotz)....Pages 1-8
 Can We Screen and Still Reduce Overdiagnosis?  (Peter Ka-Fung Chiu, Monique J. Roobol)....Pages 9-20
 The Role of Fear in Overdiagnosis and Overtreatment  (Iona Heath)....Pages 21-29
 Ethical and Legal Considerations in Active Surveillance for Prostate Cancer  (Lionne D. F. Venderbos)....Pages 31-39
 Gleason 6 Tumors Should Still Be Labeled as Cancer  (Angelo M. De Marzo, Jonathan I. Epstein)....Pages 41-52
 Risk-Based Selection for Active Surveillance  (Jan F. M. Verbeek, Monique J. Roobol, Ewout W. Steyerberg)....Pages 53-64
 Surveillance at the Margins: Management of High-Volume Gleason 6, PSA > 10, or Gleason 3 + 4  (Laurence Klotz)....Pages 65-69
 How Should Patients on Active Surveillance Be Followed?  (Frank-Jan H. Drost, Monique J. Roobol, Leonard P. Bokhorst)....Pages 71-81
 Triggers for Intervention  (Tuomas Mirtti, Hanna Vasarainen, Antti Rannikko)....Pages 83-94
 MR Imaging in Prostate Tumor Volume Assessment: How Accurate?  (Ivo G. Schoots, Theo H. van der Kwast)....Pages 95-109
 Can MRI Replace Biopsy in Men on Surveillance?  (Francesco Giganti, Vasilis Stavrinides, Caroline M. Moore)....Pages 111-119
 Tissue-Based Markers for Risk Prediction  (Chad A. Reichard, Eric A. Klein)....Pages 121-133
 International AS Registry: The Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative  (Sophie M. Bruinsma, Daan Nieboer, Tim Hulsen, Liying Zhang, Rachelle Kirk-Burnnand, Sam Gledhill et al.)....Pages 135-147
 Better-Informed Decision-Making to Optimize Patient Selection  (Lara Bellardita, Paola Dordoni, Letizia De Luca, Julia Paola Menichetti Delor, Riccardo Valdagni)....Pages 149-167
 How Does QoL Compare Between Surveillance and Active Treatment?  (Lionne D. F. Venderbos, Stephanie D. Brandhof, Ida J. Korfage)....Pages 169-181
 The Potential Benefits of Diet and Physical Activity Among Active Surveillance Patients with Low-Burden Prostate Cancer  (Stacey A. Kenfield, David Tat, June M. Chan)....Pages 183-198
 Is There a Role for Pharmacologic Manipulation to Prevent Progression in Men on Active Surveillance? The Role of 5-ARIs, Statins, and Metformin  (Roy Mano, David Margel)....Pages 199-206
 The Update of Active Surveillance Around the World: Utilization and Outcomes  (Jeffrey J. Tosoian, Ridwan Alam, Abbey Lepor, Stacy Loeb)....Pages 207-216
 Tissue Preservation: Active Surveillance and Focal Therapy as Complimentary Strategies  (Juan Gómez Rivas, Mark Emberton)....Pages 217-227
 The Economics of Active Surveillance for Prostate Cancer  (Robert B. Lurvey, Marc A. Dall’Era)....Pages 229-237
 Research Questions in Active Surveillance  (Laurence Klotz)....Pages 239-241
Back Matter ....Pages 243-250